Janet K. Coller

3.1k total citations
78 papers, 2.4k citations indexed

About

Janet K. Coller is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Janet K. Coller has authored 78 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 25 papers in Pharmacology and 17 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Janet K. Coller's work include Pharmacogenetics and Drug Metabolism (24 papers), Drug Transport and Resistance Mechanisms (16 papers) and Oral health in cancer treatment (15 papers). Janet K. Coller is often cited by papers focused on Pharmacogenetics and Drug Metabolism (24 papers), Drug Transport and Resistance Mechanisms (16 papers) and Oral health in cancer treatment (15 papers). Janet K. Coller collaborates with scholars based in Australia, United States and United Kingdom. Janet K. Coller's co-authors include Andrew A. Somogyi, Mark R. Hutchinson, Daniel T. Barratt, Joanne M. Bowen, Rachel J. Gibson, Hannah R. Wardill, Benedetta C. Sallustio, Kate R. Secombe, David Foster and Lona Louring Christrup and has published in prestigious journals such as Pain, International Journal of Cancer and British Journal of Pharmacology.

In The Last Decade

Janet K. Coller

78 papers receiving 2.4k citations

Peers

Countries citing papers authored by Janet K. Coller

Since Specialization

Citations

This map shows the geographic impact of Janet K. Coller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet K. Coller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet K. Coller more than expected).

Fields of papers citing papers by Janet K. Coller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet K. Coller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet K. Coller. The network helps show where Janet K. Coller may publish in the future.

Co-authorship network of co-authors of Janet K. Coller

This figure shows the co-authorship network connecting the top 25 collaborators of Janet K. Coller. A scholar is included among the top collaborators of Janet K. Coller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet K. Coller. Janet K. Coller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical data 2024 ·Clinical Nutrition ESPEN ·(unknown), Hannah R. Wardill, Janet K. Coller, Joanne M. Bowen	1
2	Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy 2023 ·Cancer Chemotherapy and Pharmacology ·(unknown), Joanne M. Bowen, Rachel J. Gibson, (unknown), Kate R. Secombe, (unknown), Richard M. Logan, Jonathan Tuke, (unknown), (unknown), Christos S. Karapetis, Dorothy Keefe, Janet K. Coller	3
3	Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity 2022 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), (unknown), Janet K. Coller, Anthony Wignall, Clive A. Prestidge, Joanne M. Bowen	5
4	Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment 2021 ·Cancer Chemotherapy and Pharmacology ·Kate R. Secombe, (unknown), (unknown), Hannah R. Wardill, Rachel J. Gibson, Janet K. Coller, Joanne M. Bowen	6
5	Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability 2021 ·Inflammatory Intestinal Diseases ·(unknown), Joanne M. Bowen, Kate R. Secombe, Janet K. Coller, Maxime François, Wayne R. Leifert, Hannah R. Wardill	4
6	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome 2020 ·Integrative Cancer Therapies ·Kate R. Secombe, Ysabella Van Sebille, Bronwen J. Mayo, Janet K. Coller, Rachel J. Gibson, Joanne M. Bowen	48
7	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines 2019 ·Supportive Care in Cancer ·Joanne M. Bowen, Rachel J. Gibson, Janet K. Coller, Nicole M. A. Blijlevens, Paolo Bossi, Noor Al‐Dasooqi, Emma Bateman, Karen Chiang, (unknown), Bronwen J. Mayo, Andrea M. Stringer, Wim J. E. Tissing, Hannah R. Wardill, Ysabella Van Sebille, Vinisha Ranna, Anusha Vaddi, Dorothy Keefe, Rajesh V. Lalla, Karis Kin Fong Cheng, Elad Sharon	51
8	The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity 2018 ·International Journal of Cancer ·Kate R. Secombe, Janet K. Coller, Rachel J. Gibson, Hannah R. Wardill, Joanne M. Bowen	61
9	Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy 2018 ·Cancer Chemotherapy and Pharmacology ·(unknown), Rachel J. Gibson, Joanne M. Bowen, Janet K. Coller	5
10	Validation of an LC–MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies 2013 ·Journal of Chromatography B ·Zaipul I. Md Dom, Benjamin Noll, Janet K. Coller, Andrew A. Somogyi, Graeme Russ, Dennis A. Hesselink, Teun van Gelder, Benedetta C. Sallustio	19
11	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics 2012 ·Pharmacogenomics and Personalized Medicine ·Daniel T. Barratt, Janet K. Coller, (unknown), (unknown), Jason M. White, David Foster, Andrew A. Somogyi	41
12	Measurement of Cyclosporine A in Rat Tissues and Human Kidney Transplant Biopsies—A Method Suitable for Small (<1 mg) Samples 2011 ·Therapeutic Drug Monitoring ·Benjamin Noll, Janet K. Coller, Andrew A. Somogyi, Raymond G. Morris, Graeme Russ, Dennis A. Hesselink, Teun van Gelder, Benedetta C. Sallustio	14
13	OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence 2011 ·Pharmacogenetics and Genomics ·Janet K. Coller, Sharon Cahill, (unknown), Aaron L. Farquharson, Marie Longo, (unknown), Thomas Sullivan, Andrew A. Somogyi, Jason M. White	37
14	The combined impact ofCYP2C19andCYP2B6pharmacogenetics on cyclophosphamide bioactivation 2010 ·British Journal of Clinical Pharmacology ·Nuala A. Helsby, (unknown), (unknown), Janet K. Coller, May Ching Soh, Peter Gow, (unknown), Malcolm D. Tingle	42
15	Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence 2009 ·Pharmacogenetics and Genomics ·Liang Liu, Mark R. Hutchinson, Jason M. White, Andrew A. Somogyi, Janet K. Coller	37
16	TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells 2007 ·Breast Cancer Research and Treatment ·Miriam Buck, Janet K. Coller, Thomas E. Mürdter, Michel Eichelbaum, Cornelius Knabbe	21
17	Effect of CYP2D6 metabolizer status on the disposition of the (+) and (−) enantiomers of perhexiline in patients with myocardial ischaemia 2007 ·Pharmacogenetics and Genomics ·Sally C. Inglis, Megan K. Herbert, (unknown), Janet K. Coller, (unknown), John D. Horowitz, Raymond G. Morris, Robert Milne, Andrew A. Somogyi, Benedetta C. Sallustio	5
18	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography 2006 ·Journal of Chromatography B ·(unknown), Megan K. Herbert, Julie A. Culbert, Simon M. Pyke, Janet K. Coller, Andrew A. Somogyi, Robert Milne, Benedetta C. Sallustio	14
19	The influence of CYP2D6 genotype on trough plasma perhexiline and cis‐OH‐perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia 2005 ·British Journal of Clinical Pharmacology ·(unknown), Janet K. Coller, (unknown), Andrew A. Somogyi, John D. Horowitz, Benedetta C. Sallustio	10
20	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity 2003 ·British Journal of Clinical Pharmacology ·Janet K. Coller, (unknown), Kathrin Klein, Renzo Wolbold, Andreas K. Nüssler, P. Neuhaus, Ulrich M. Zanger, Michel Eichelbaum, Thomas E. Mürdter	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact